Harnessing Neoantigens for Individualized Cancer Immunotherapy
An iQue On-Demand Webinar
Neoantigens resulting from the presentation of mutated peptides on MHC molecules are attractive therapeutic targets. They are tumor specific, elicit CD8 and CD4 T cell responses by being recognized as foreign by the immune system, and there is emerging evidence that neoantigens are drivers of protective immunity to cancer.
A challenge with harnessing neoantigens is that most neoantigens are patient tumor specific and require the development of individualized immunotherapy.
This webinar provides:
- An overview of the approaches currently in development, which target neoantigens
- A discussion on the rules defining immunogenic neoepitopes
- Review of the current efforts aimed at improving neoantigen selection methods
- Study of the definition of the mechanistic drivers of efficacy, following preclinical study vaccination with the RNA-LPX vaccine
Lélia Delamarre, Ph.D.
Senior Scientist, Cancer Immunology Department
Lélia Delamarre is a Senior Scientist in the Cancer Immunology Department at Genentech. Her research team investigates the mechanisms by which dendritic cells elicit T cell responses and how vaccine platforms can be optimized to generate the magnitude, breadth, and quality needed for cancer protective T cell immunity.
Her group also focuses on the identification and characterization of cancer neoantigens that elicit anti-tumor efficacy with the goal of improving methods to select neoantigens for individualized immunotherapy.
Lélia Delamarre obtained a Ph.D. in Virology from Pierre and Marie Curie University in France, and she completed her postdoctoral training at Yale University, where she studied the cell biology of antigen presentation in dendritic cells, before joining Genentech in 2007.